Elanco/$ELAN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Elanco
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Ticker
$ELAN
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
9,225
ISIN
US28414H1032
Website
Elanco Metrics
BasicAdvanced
$7.4B
19.87
$0.75
1.68
-
Price and volume
Market cap
$7.4B
Beta
1.68
52-week high
$15.70
52-week low
$8.02
Average daily volume
5.2M
Financial strength
Current ratio
2.711
Quick ratio
1.219
Long term debt to equity
68.487
Total debt to equity
69.18
Interest coverage (TTM)
1.17%
Profitability
EBITDA (TTM)
863
Gross margin (TTM)
54.89%
Net profit margin (TTM)
8.43%
Operating margin (TTM)
5.53%
Effective tax rate (TTM)
30.41%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
1.14%
Return on equity (TTM)
6.01%
Valuation
Price to earnings (TTM)
19.868
Price to revenue (TTM)
1.663
Price to book
1.16
Price to tangible book (TTM)
-4.13
Price to free cash flow (TTM)
22.11
Free cash flow yield (TTM)
4.52%
Free cash flow per share (TTM)
67.34%
Growth
Revenue change (TTM)
1.42%
Earnings per share change (TTM)
-128.31%
3-year revenue growth (CAGR)
-2.31%
3-year earnings per share growth (CAGR)
-0.84%
What the Analysts think about Elanco
Analyst ratings (Buy, Hold, Sell) for Elanco stock.
Bulls say / Bears say
Stifel raised Elanco's price target to $17, citing gains in parasiticide market share and strong performance of products like Credelio Quattro, Advantage, and Seresto. (Investing.com)
Elanco's restructuring plan, including the divestiture of its aqua business, is expected to result in annualized net savings of $30 to $35 million, allowing the company to focus on higher-growth areas. (TradingView)
The company received multiple regulatory approvals for new products, including Bovaer, Zenrelia, Credelio Quattro, and Experior, which are anticipated to drive future growth. (TradingView)
Elanco is under investigation for potential securities fraud related to misleading statements about FDA approvals, leading to a significant stock price decline. (GuruFocus)
Barclays issued a pessimistic forecast for Elanco's stock price, reflecting concerns about the company's future performance. (Techdows)
Elanco faces operational risks from manufacturing problems and capacity imbalances, which can lead to product launch delays, inventory shortages, and increased costs. (TradingView)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Elanco Financial Performance
Revenues and expenses
Elanco Earnings Performance
Company profitability
Elanco News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Elanco stock?
Elanco (ELAN) has a market cap of $7.4B as of July 15, 2025.
What is the P/E ratio for Elanco stock?
The price to earnings (P/E) ratio for Elanco (ELAN) stock is 19.87 as of July 15, 2025.
Does Elanco stock pay dividends?
No, Elanco (ELAN) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Elanco dividend payment date?
Elanco (ELAN) stock does not pay dividends to its shareholders.
What is the beta indicator for Elanco?
Elanco (ELAN) has a beta rating of 1.68. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.